Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"Dasatinib"”.
-
Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia
… kinase inhibitors (BCR-ABL–KIs) imatinib, dasatinib and nilotinib induce prolonged remissions in CML but poor leukemia-reduction and relapse-control in Ph+ ALL. The relative primary BCR-ABL–KI-resistance in Ph+ ALL patients carrying predominantly BCR-ABLWT disease cannot be attributed to …
-
Combination of Dasatinib and Dexamethasone targets the myeloma plasma cell through its interaction with the bone marrow microenvironment
… reduced osteoblast differentiation and function. Dasatinib, a multi-targeted tyrosine kinase inhibitor, inhibits the Src family kinases, Abl kinase, c- kit and PDGFR. I hypothesised, combining Dasatinib with a cytotoxic agent dexamethasone; through direct antimyeloma effect, disruption of …
-
Developing Targeted Therapies for T-cell Acute Lymphoblastic Leukemia
… T-ALL population that showed strong response to dasatinib, a known ABL1 inhibitor. Importantly, none of the T-ALL responders harbored BCR-ABL1 or fusions predicted to respond to ABL1 inhibitors. We identified differences in somatic genetic alterations between dasatinib responders and …
-
Regulation and Targeting of Fyn in Human Cutaneous Squamous Cell Carcinoma
… using siRNA or the clinical SFK inhibitor Dasatinib increased cell-cell adhesion in HaCaT-Ras cells over 6-fold (p<0.001) through a rapid (5-60 min.) increase in the cortical F-actin cytoskeleton. Treatment of the HaCaT-Fyn cells with Dasatinib also resulted in upregulation of F-actin. …
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
… and the multi-target tyrosine kinase inhibitor dasatinib. Significantly higher EGFR expression was detected in TNBC compared to HER-2 positive breast cancer cell lines. EGF treatment stimulated phospho-EGFR which was inhibited by gefitinib. Sensitivity to gefitinib was associated with decreases …
-
Characterizing The Effect of Dasatinib On Anti-Tumor Immune Response and Exploring The Potential of Combining Targeted Therapy and Immunotherapy In A C-Kit Mutant Mastocytoma Model
… the therapeutic effect of the c-KIT inhibitor dasatinib is substantially dependent on the anti- tumor T cell response. Even though the direct effect of dasatinib on antigen-driven T cell expansion is inhibitory, 3-day dasatinib treatment significantly increased the proportion of tumor-specific …
-
An in vivo RNAi therapy screen identifies novel mediators of leukemia-microenvironment interaction
… genetic mediators of response to the TKI dasatinib in a transplantable syngeneic mouse model of BCR-ABLI+ BCP-ALL. The unique combination of a longitudinal screen design and independent component analysis of screening data allowed for identification of hairpins that have distinct behavior …
-
Ocorrência de eventos adversos relacionados a inibidores de tirosina quinase de primeira e segunda geração : revisão de literatura
… tyrosine kinase inhibitors second generation, dasatinib, and nilotinib. In this study, the recent li terature data were analyzed four years related adverse events associated with imatinib, dasatinib, and nilotinib. They were found 152 articles, of which 24 were used international articles are …
-
A pathways-based approach identifying determinants of drug resistance in oesophageal adenocarcinoma
… This identified the additive effect of combining dasatinib with cisplatin in an OAC setting. Src inhibition using dasatinib and saracatinib was assessed with MTT viability assays, assessing the efficacy of combining Src-inhibition with traditional chemotherapies. CI values were generated to assess …
-
Vitamin D Levels Affect Survival in a BCR-ABL Acute Lymphoblastic Leukemia Mouse Model but Do Not Cause Vitamin-Drug Interactions
… agents such as dexamethasone (DEX) and dasatinib which are given orally to the patients were chosen to study the effect of VD3 status on systemic exposure of these CYP3A4 substrates.</p> <p>In C57BL/6 mice, we performed dexamethasone PK study, where we observed male VD3 deficient mice …
-
Alterazioni immunologiche su cellule mesenchimali stromali e linee cellulari di Leucemia Mieloide Cronica (LMC)
… dimostrato che i TKI, in particolare Imatinib e Dasatinib, hanno effetti differenziali sulle CML-LSC attraverso la regolazione della fosforilazione ossidativa mitocondriale (OXPHOS) che può rappresentare un nuovo target per l'eliminazione delle CML-LSC durante la sospensione del trattamento …
-
Targeting Opioid Receptor Signal Transduction to Produce Sustained Analgesia
… was reduced in BAR2+/- and BAR2-/- VTA neurones. Dasatinib and PP2 (c-Src tyrosine kinase inhibitors) prevented the development of morphine tolerance in WT and MOP+/- mice and dasatinib caused its reversal in the latter. The drugs had no significant analgesic effect alone. Dasatinib did not affect …
-
Expression and function of drug transporters in primitive CML cells
… for any of the transporters. In contrast, dasatinib was shown to be a substrate for ABCG2 and MRP1, but had no effect on MDR1. Therefore activity and concentration of dasatinib but not IM or nilotinib may be altered by the activity of these proteins. In keeping with their inhibitory …
-
Signal Regulation By Cd38, Lyn, And Mapk-Associated Molecules During All-Trans Retinoic Acid-Induced Differentiation Of Acute Myelogenous Leukemia Cells
… Finally we found that the Lyn inhibitors PP2 and dasatinib enhanced ATRA-induced differentiation. Co-treatment with ATRA plus either inhibitor upregulated total Lyn and c-RafpS259, and increased associations between Lyn/c-Raf and cRaf/ERK. This was consistent with increased c-Raf C-terminus …
-
Development and application of novel analytical methods for molecularly targeted cancer therapeutics
… quantification method it was established that dasatinib, an agent used in treatment of chronic myelogenous leukaemia, is a substrate of ABC transporters P-gp and BCRP but not of MRP-1, and that dasatinib does not inhibit these transporters at clinically relevant concentrations. Another Tyrosine …
-
Mechanism of resistance to tyrosine kinase inhibitors in philadelphia-positive acute lymphblastic leukaemia (all): from genetic alterations to impaired RNA editing
… could associate with resistance to imatinib and dasatinib. Bone marrow and peripheral blood samples from 46 adult patients (median age 55 yrs, 18-76) with Ph+ ALL at diagnosis and during treatment with imatinib (16 pts) or dasatinib (30 pts) were collected. We set up a fast, high-throughput …
-
Proteasome inhibition in chronic myeloid leukaemia
… Significant synergy is seen when bortezomib and dasatinib are used in combination. We also demonstrate that bortezomib is effective in inhibiting proteasome activity and inducing apoptosis in cell lines expressing BCR-ABL mutations, including T315I. Therefore we believe that bortezomib offers a …
-
Integrin-Mediated Mechanotransduction Controls Activation of Yap and Invasive Growth of Breast Cancer
… oncogenic signaling. Finally, administration of Dasatinib combined with Lapatinib significantly increases the efficacy of HER2 inhibition in the MMTV-Neu mouse model of HER2+ breast cancer. These findings reveal a major mechanism through which the Hippo tumor suppressive pathway is disabled in …
-
Phenotypic screening and AI uncovers modulators of YAP and TAZ activity in glioblastoma
… consisted of the Src family kinase inhibitors Dasatinib and eCF506 which showed dual reduction in YAP and TAZ nuclear translocation and subsequently reduction in cell proliferation through cell cycle arrest in both 2-dimensional and 3- dimensional spheroid assays. Another validated hit compound …
Page 1 of 2